Publications

Role of clonal occurrences of multi-drug-resistance (MDR) in the MYSTIC Programme (USA; 1999-2003), Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Tn21-like elements disseminating carbapenemase genes in Italy: report from the SENTRY antimicrobial surveillance programme, Lead author: Toleman MA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Contribution of outer membrane protein alterations and beta-lactamases in carbapenem-resistant Acinetobacter spp., Lead author: Castanheira M, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Characterisation of two novels 6′-N-aminoglycoside acetyltransferase genes, aac(6′)-30 and aac(6′)-31, found in blaIMP-16 and blaIMP-1 Pseudomonas aeruginosa strains carrying integron, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Characterisation of In77, a class 1 plasmid-located integron carrying the novel metallo-beta-latamase gene blaGIM-1, Lead author: Castanheira M, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Tn501-like transposons carrying novel blaVIM-4 metallo-&#223-lactamase (MBL) gene cassettes in Poland and GIM-1 in Germany: report from the SENTRY antimicrobial surveillance programme, Lead author: Toleman MA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Biochemical characterisation of VIM-7, a new VIM variant produced by a Pseudomomas aeruginosa clinical isolate from Texas, Lead author: Castanheira M, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Daptomycin in vitro activity tested against 2,221 Gram-positive strains collected from European hospitals, 2002, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Pharmacodynamics of levofloxacin (usual and high dose) and moxifloxacin versus Streptococcus pneumoniae from the SENTRY antimicrobial surveillance program (2002-2003) in elderly patients using Monte Carlo Analysis and population pharmacokinetics, Lead author: Owens Jr. RC, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

The emergence of VIM-2 in Latin American hospitals: report from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Endemic and epidemic occurrences of metallo-beta-lactamases in Japanese medical centres (1998-2002): report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial activity of the novel cephalosporin LB11058 tested against pathogens commonly associated with bacterial meningitis, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Substrate inhibition of the Pseudomonas aeruginosa metallo-beta-lactamase, SPM-1, in acidic and alkaline conditions, Lead author: Murphy TA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Biochemical characterisation of IMP-16, a novel IMP variant harboured in a class I integron of a Pseudomonas aeruginosa clinical isolate from Brazil, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Frequency and antimicrobial susceptibility of bacterial pathogens isolated from bloodstream infections in haematology-oncology patients: results from the Latin America SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Andrade SS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Frequency of occurrence and antimicrobial susceptibility profile of pathogens causing bloodstream infections in paediatric patients from Latin America: report of SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Gales AC, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial spectrum and activity of NVP PDF-713 (PDF7), a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Potential utility of a peptide deformylase inhibitor, NVP PDF-713 (PDF7) against oxazolidinone-resistant or streptogramin-resistant Gram-positive isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of quality control guidelines for MIC dilution and disk diffusion methods when testing NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of dry-form commercial reagent reproducibility and MIC validations for NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Moet G, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Once-weekly dalbavancin in catheter-related bloodstream infections: microbiological findings, Lead author: Goldstein BP, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Evaluations of Dalbavancin (DAL) activity and spectrum tested against European isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary Staphylococci, Streptococci and Enterococci, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial activity of tigecycline (GAR-936) tested against enterobacteriaceae, and selected non-fermentative Gram-negative bacilli, a worldwide sample, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Activity of tigecycline tested against clinical isolates of Haemophilus influenzae, Moraxella catarrhalis and Neisseria menigitidis, a worldwide perspective, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Potency and Spectrum Re-Evaluation of Cefdinir Tested Against Pathogens Causing Skin and Soft Tissue Infections (SSTI):A Sample of North American Isolates, Lead author: Jones RN, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Contemporary Cefdinir Activity against North American Isolates from Community-acquired Urinary Tract Infections (CA-UTI), Lead author: Sader HS, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Increasing Resistance (R) of Pseudomonas aeruginosa (PSA), Staphylococcus aureus (SA), Klebsiella spp. (KSP), and Acinetobacter spp. (ASP) in Patients with Pneumonia in Latin America (LA): Report from the SENTRY Antimicrobial Surveillance Program, 2002, Lead author: Fritsche TR, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Antimicrobial Susceptibility of Burkholderia cepacia in Latin America: Report from the SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Sibert S, presented at 11th annual International Congress on Infectious Diseases (ICID), March 4 – 7, 2004, Cancun, Mexico

Antimicrobial spectrum and activity of NVP PDF-713, A novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. by Jones RN, Fritsche TR and Sader HS published in Diagn. Microbiol Infect. Dis. 2004; 49 (1): 63-65

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. by Jones RN, Moet GJ, Sader HS and Fritsche TR published in J. Antimicrob. Chemother. 2004; 53 (5): 804-807

Daptomycin activity and spectrum: A worldwide sample of 6,737 clinical Gram-positive organisms. by Streit JM, Jones RN, Sader HS published in J. Antimicrob. Chemother. 2004; 53 (4): 669-674

Letters to the editor: First isolation of bla_VIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. by Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, Walsh TR and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (4): 1433-1434

A pragmatic approach to identify extended-spectrum beta-lactamse-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents. by Yu, W-L, Chuang, Y-C, Jones, RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (4): 277-282

Pseudomonas aeruginosa strains harbouring an unusual bla_VIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). by Patzer J, Toleman MA, Deshpande LM, Kaminska W, Dzierzanowska D, Bennett PM, Jones RN and Walsh TR published in J. Antimicrob. Chemother. 2004; 53 (3): 451-456

Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI226), a novel antimicrobial peptide. by Anderegg T.R., Fritsche TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (3): 1386-1387

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. by Streit JM, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 137-143

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 101-105

Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002). by Rhomberg PR, Fritsche TR, Sader HS, Jones RN published in Antibiot. Clin. 2003; 7 (Suppl 2): 2-7

Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: Report from the Garenoxacin International Bridging Study. by Jones RN, Gordon KA, Biedenbach DJ published in J. Antimicrob. Chemother. 2004; 53 (2): 258-265

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). by Mutnick AH, Rhomberg PR, Sader HS, Jones RN published in J. Antimicrob. Chemother. 2004; 53 (2): 290-296

Disk diffusion quality control guidelines for NVP PDF-713: A novel peptide deformylase inhibitor. by Anderegg TR, Jones RN, The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 2004; 48 (1): 55-57

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. by Jones RN, Streit JM and Fritsche TR published in Int. J. Antimicrob. Agents. 2004; 23 (2): 197-199

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States Medical Centres. by Rhomberg PR, Jones RN, Sader HS and MYSTIC Programme Study Group published in Int. J. Antimicrob. Agents 2004; 23 (1): 52-59

Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. by Anderegg TR and Jones RN published in Int. J. Antimicrob. Agents 2004; 23 (1): 6-10

Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). by Kirby JT, Sader HS, Walsh TR and Jones RN published in J. Clin. Microbiol. 2004; 42 (1): 445-448

Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. by Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (1): 28-52

Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan. by Yu W-L, Wu L-T, Pfaller MA, Winokur PL and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 362-363

bla_VIM-7, an evolutionary distinct metallo-beta-lactamsae gene in a Pseudomonas aeruginosa isolate from the United States. by Toleman MA, Rolston K, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2004; 48 (1): 329-332

Are Enterococcus faecalis strains with vat(E) in poultry a reservoir for human streptogramin resistance? vat(E) occurrence in human enterococcal bloodstream infections in North America (SENTRY Antimicrobial Surveillance Program, 2002). by Jones RN, Deshpande LM published in Antimicrob. Agents Chemother. 2004; 48 (1): 360-361